PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Clinical and Molecular Hepatology10.3350/cmh.2012.18.2.1952012182195Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naïve patients with chronic hepatitis B infectionWon Gil Chung, Hong Joo Kim, Young Gil Choe, Hyo Sun Seok, Chang Wook Chon, Yong Kyun Cho, Byung Ik Kim, Young Yool Kohhttp://synapse.koreamed.org/pdf/10.3350/cmh.2012.18.2.195, http://synapse.koreamed.org/DOIx.php?id=10.3350/cmh.2012.18.2.195
Viral Hepatitis: Chronic Hepatitis C10.1007/978-3-030-03757-4_4201965-95Current Therapy of Chronic Hepatitis C Virus in Treatment-Naive PatientsAlhareth AlJuboori, Satinder Kaur, Veysel Tahanhttp://link.springer.com/content/pdf/10.1007/978-3-030-03757-4_4
Clinical Therapeutics10.1016/j.clinthera.2006.02.0122006282184-203Entecavir for the treatment of chronic hepatitis B virus infectionS. James Matthewshttps://api.elsevier.com/content/article/PII:S014929180600052X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S014929180600052X?httpAccept=text/plain
Current Hepatitis Reports10.1007/s11901-012-0127-5201211290-94Partial Response to Entecavir and Tenofovir in Naïve Patients with Chronic Hepatitis B: Clinical Relevance and ManagementPietro Lampertico, Mauro Viganò, Massimo Colombohttp://link.springer.com/content/pdf/10.1007/s11901-012-0127-5.pdf, http://link.springer.com/article/10.1007/s11901-012-0127-5/fulltext.html, http://link.springer.com/content/pdf/10.1007/s11901-012-0127-5
Drug Design, Development and Therapy10.2147/dddt.s41423201313Clinical utility of entecavir for chronic hepatitis B in Chinese patientsJi-yao Wanghttps://www.dovepress.com/getfile.php?fileID=18448
Gastroenterology10.1016/s0016-5085(15)31685-120151484S-502Su1414 A Randomized Controlled Trial to Compare the Efficacy and Safety of Entecavir Versus Tenofovir Treatment in Naïve Chronic Hepatitis B PatientsTassanee Sriprayoonhttps://api.elsevier.com/content/article/PII:S0016508515316851?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0016508515316851?httpAccept=text/plain
Journal of Hepatology10.1016/s0168-8278(05)81921-x200542184509 The efficacy of entecavir is similar regardless of disease-related baseline subgroups in treatment of nucleo side-naive, HBeAg(+) and HBeAg(−) patients with chronic hepatitis Bhttps://api.elsevier.com/content/article/PII:S016882780581921X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S016882780581921X?httpAccept=text/plain
Journal of Hepatology10.1016/s0168-8278(05)81940-3200542192529 Entecavir (ETV) demonstrates consistent responses throughout baseline demographic subgroups for the treatment of nucleoside-naive, HBeAg(+) and HBeAg(-) patients with chronic hepatitis Bhttps://api.elsevier.com/content/article/PII:S0168827805819403?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0168827805819403?httpAccept=text/plain
Hepatology10.1002/hep.2477820115462281-2282Corrections: Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological responsehttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.24778
Liver International10.1111/j.1478-3231.2010.02245.x2009306834-840Comparison between clevudine and entecavir treatment for antiviral-naïve patients with chronic hepatitis BHong Joo Kim, Dong Il Park, Jung Ho Park, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kimhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1478-3231.2010.02245.x